References

1. Falih Soliman N, Jasim Mohamad B. Clinical and histopathological characteristics of colorectal cancer in Iraq between 2015-2021. Arch Razi Inst. 2022; 77(6):2407-13. [DOI:10.22092/ARI.2022.358613.2263] [PMID]
2. Kim J, Lee HK. Potential role of the gut microbiome in colorectal cancer progression. Front Immunol. 2022; 12:807648. [DOI:10.3389/fimmu.2021.807648] [PMID]
3. Leylabadlo HE, Ghotaslou R, Feizabadi MM, Farajnia S, Moaddab SY, Ganbarov K, et al. The critical role of Faecalibacterium prausnitzii in human health: An overview. Microb Pathog. 2020; 149:104344. [DOI:10.1016/j.micpath.2020.104344] [PMID]
4. Ahmad Kendong SM, Raja Ali RA, Nawawi KNM, Ahmad HF, Mokhtar NM. Gut dysbiosis and intestinal barrier dysfunction: Potential explanation for early-onset colorectal cancer. Front Cell Infect Microbiol. 2021; 11:744606. [DOI:10.3389/fcimb.2021.744606] [PMID]
5. Chen K, McCulloch J, Das Neves R, Rodrigues G, Hsieh WT, Gong W, et al. The beneficial effects of commensal E. coli for colon epithelial cell recovery are related with Formyl peptide receptor 2 (Fpr2) in epithelial cells. Gut Pathog. 2023; 15(1):28.[DOI:10.1186/s13099-023-00557-w] [PMID]
6. Lichtenstern CR, Lamichhane-Khadka R. A tale of two bacteria - Bacteroides fragilis, Escherichia coli, and colorectal cancer. Front Bacteriol. 2023; 2:1229077. [DOI:10.3389/fbrio.2023.1229077]
7. Mohamed ET, Mundhada H, Landberg J, Cann I, Mackie RI, Nielsen AT, et al. Generation of an E. coli platform strain for improved sucrose utilization using adaptive laboratory evolution. Microb Cell Fact. 2019; 18(1):116. [DOI:10.1186/s12934-019-1165-2] [PMID]
8. Goubet AG. Could the tumor-associated microbiota be the new multi-faceted player in the tumor microenvironment? Front Oncol. 2023; 13:1185163. [DOI:10.3389/fonc.2023.1185163] [PMID]
9. Schorr L, Mathies M, Elinav E, Puschhof J. Intracellular bacteria in cancer-prospects and debates. NPJ Biofilms Microbiomes. 2023; 9(1):76. [DOI:10.1038/s41522-023-00446-9] [PMID]
10. Kaźmierczak-Siedlecka K, Marano L, Merola E, Roviello F, Połom K. Sodium butyrate in both prevention and supportive treatment of colorectal cancer. Front Cell Infect Microbiol. 2022; 12:1023806. [DOI:10.3389/fcimb.2022.1023806] [PMID]
11. Bordonaro M. Further analysis of p300 in mediating effects of Butyrate in Colorectal Cancer Cells. J Cancer. 2020; 11(20):5861-6. [DOI:10.7150/jca.47160] [PMID]
12. Orlov YP, Butrov AV, Sviridov SV, Afanasyev VV, Kondratiev AN, Tsentsiper LM, et al. Succinate and succinate dehydrogenase as a “fulcrum” in the Krebs cycle in critical conditions. Antibiot Chemother. 2023; 68(1-2):57-68. [DOI:10.37489/0235-2990-2023-68-1-2-57-68]
13. Sica V, Bravo-San Pedro JM, Izzo V, Pol J, Pierredon S, Enot D, et al. Lethal poisoning of cancer cells by respiratory chain inhibition plus dimethyl α-Ketoglutarate. Cell Rep. 2019; 27(3):820-34.e9. [DOI:10.1016/j.celrep.2019.03.058] [PMID]
14. Xi Y, Jing Z, Wei W, Chun Z, Quan Q, Qing Z, et al. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer. 2021; 21(1):127. [DOI:10.1186/s12885-021-07845-1] [PMID]
15. Zheng L, Zhu ZR, Sneh T, Zhang WT, Wang ZY, Wu GY, et al. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma. J Clin Invest. 2023; 133(11):e165028. [DOI:10.1172/JCI165028] [PMID]
16. Roupar D, González A, Martins JT, Gonçalves DA, Teixeira JA, Botelho C, et al. Modulation of Designed Gut Bacterial Communities by Prebiotics and the Impact of Their Metabolites on Intestinal Cells. Foods. 2023; 12(23):4216.[DOI:10.3390/foods12234216] [PMID]
17. Baryła M, Semeniuk-Wojtaś A, Róg L, Kraj L, Małyszko M, Stec R. Oncometabolites-A link between cancer cells and tumor microenvironment. biology (Basel). 2022; 11(2):270. [DOI:10.3390/biology11020270] [PMID]
18. Ternes D, Tsenkova M, Pozdeev VI, Meyers M, Koncina E, Atatri S, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022; 4(4):458-75. [DOI:10.1038/s42255-022-00558-0] [PMID]
19. Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016; 537(7621):544-7. [DOI:10.1038/nature19353] [PMID]
20. He J, Han Z, Luo W, Shen J, Xie F, Liao L, et al. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer. Front Immunol. 2023; 13:998447. [DOI:10.3389/fimmu.2022.998447] [PMID]
21. Lu YW, Hou XL, Koo HM, Chao WT. Dasatinib suppresses collective cell migration through the coordination of focal adhesion and E-cadherin in colon cancer cells. Heliyon. 2023; 10(1):e23501 [DOI:10.1016/j.heliyon.2023.e23501] [PMID]
22. Tarashi S, Siadat SD, Ahmadi Badi S, Zali M, Biassoni R, Ponzoni M, et al. Gut bacteria and their metabolites: Which one is the defendant for colorectal cancer? Microorganisms. 2019; 7(11):561 [DOI:10.3390/microorganisms7110561] [PMID]
23. Thirunavukkarasan M, Wang C, Rao A, Hind T, Teo YR, Siddiquee AA, et al. Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells. Plos One. 2017; 12(10):e0186334. [DOI:10.1371/journal.pone.0186334] [PMID]